


# BMJ Open Development and presentation of an objective risk stratification tool for healthcare workers when dealing with the COVID-19 pandemic in the UK: risk modelling based on hospitalisation and mortality statistics compared with epidemiological data

W David Strain <sup>1,2</sup>, Janusz Jankowski,<sup>3</sup> Angharad P Davies,<sup>4</sup> Peter English,<sup>5</sup> Ellis Friedman,<sup>6</sup> Helena McKeown,<sup>7</sup> Su Sethi,<sup>8</sup> Mala Rao<sup>9</sup>

**To cite:** Strain WD, Jankowski J, Davies AP, *et al*. Development and presentation of an objective risk stratification tool for healthcare workers when dealing with the COVID-19 pandemic in the UK: risk modelling based on hospitalisation and mortality statistics compared with epidemiological data. *BMJ Open* 2021;**11**:e042225. doi:10.1136/bmjopen-2020-042225

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2020-042225>).

Received 01 July 2020  
Accepted 01 July 2021



© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

## Correspondence to

Dr W David Strain, Institute for Clinical Trials, University College London, London, UK; [d.strain@exeter.ac.uk](mailto:d.strain@exeter.ac.uk)

## ABSTRACT

**Objectives** Healthcare workers have greater exposure to SARS-CoV-2 and an estimated 2.5-fold increased risk of contracting COVID-19 than the general population. We wished to explore the predictive role of basic demographics to establish a simple tool that could help risk stratify healthcare workers.

**Setting** We undertook a review of the published literature (including multiple search strategies in MEDLINE with PubMed interface) and critically assessed early reports on preprint servers. We explored the relative risk of mortality from readily available demographics to identify the population at the highest risk.

**Results** The published studies specifically assessing the risk of healthcare workers had limited demographics available; therefore, we explored the general population in the literature. *Clinician demographics:* Mortality increased with increasing age from 50 years onwards. Male sex at birth, and people of black and minority ethnicity groups had higher susceptibility to both hospitalisation and mortality. *Comorbid disease.* Vascular disease, renal disease, diabetes and chronic pulmonary disease further increased risk. *Risk stratification tool:* A risk stratification tool was compiled using a white female <50 years with no comorbidities as a reference. A point allocated to risk factors was associated with an approximate doubling in risk. This tool provides numerical support for healthcare workers when determining which team members should be allocated to patient facing clinical duties compared with remote supportive roles.

**Conclusions** We generated a tool that provides a framework for objective risk stratification of doctors and healthcare professionals during the COVID-19 pandemic, without requiring disclosure of information that an individual may not wish to share with their direct line manager during the risk assessment process. This tool has been made freely available through the British Medical Association website and is widely used in the National Health Service and other external organisations.

## Strengths and limitations of this study

- There is an increased risk of mortality in the clinical workforce due to effects of COVID-19.
- This article outlines a simple risk stratification tool that helps to quantify an individual's biological risk.
- This tool does not incorporate other external factors, such as high-risk household members or those at higher risk of mental health issues, that may require additional consideration when allocating clinical duties in an appropriate clinical domain.
- This population-based analysis did not explain the reason for the very high risk observed in black, Asian and minority ethnic healthcare workers, suggesting there are other issues at play that require addressing.
- The risk assessment tool presented continues to be tested and validated against primary care databases—the most up-to date version will remain freely available at <https://www.bma.org.uk/media/3820/bma-covid-19-risk-assessment-tool-february-2021.pdf>.

The Health and Safety Executive mandates that all employers protect their employees from harm under the Management of Health and Safety at Work Regulations 1999. There are three key elements to this: identify what could cause the injury (the hazard), decide how likely that someone could be harmed and how seriously they are likely to be harmed (the vulnerability) and what actions can be taken to minimise this risk (the mitigation). In the current coronavirus pandemic, it is clear that COVID-19 is the agent that causes injury. The risk of harm is higher in

healthcare workers compared with the general population,<sup>1</sup> and thus action is required to minimise this risk. In the early phase of the pandemic, the Office of National Statistics reported medical practitioners had a 2.5-fold increase (95% CI, 1.5 to 4.3) in mortality compared with the average mortality from 2014 to 2018.<sup>2</sup> This compared with a 50% increased risk in the age-matched general population (HR, 1.5; 95% CI, 1.5 to 1.6). This trend was in keeping with observations in other countries of higher mortality among healthcare workers.<sup>3–7</sup>

While reasonable measures must be taken to protect all staff members from infection, individuals thought to be particularly vulnerable to infection may require modification of their practice. The Faculty of Occupational Medicine and National Health Service (NHS) Employers in England produced recommendations that all healthcare practitioners should receive an occupational risk assessment.<sup>8,9</sup> These frameworks were borne of the observation that certain ethnic groups appeared to be at higher risk than others<sup>9</sup> while recognising there are several other biological parameters, such as age, male sex, prior cardiovascular disease and diabetes, that were also associated with adverse outcomes. These predictors of hospitalisation, progression to intensive care units (ICUs) and ultimately death were reaffirmed in the Public Health England document.<sup>10</sup>

Despite the intention to improve risk assessment in healthcare settings, these frameworks failed to produce an objective tool to improve stratification across the healthcare system. The need for such a tool is highlighted by the disproportionate impact of COVID-19 on healthcare workers of black, Asian and minority ethnicity (BAME) descent. Up to 21 April 2020, 36% and 27% of the fatalities came from people of Indian Asian heritage and black African descent, respectively, despite those populations only representing 10% and 6% of the workforce. Existing data suggest that biological parameters do not account for all the increased risk, raising the possibility of cultural differences in self-assessment of risk or systemic challenges in modification of hazards for people of different ethnic background. Indeed, these cultural challenges have been proposed as a contributor to the increased risk in BAME populations.

Using published data on the demographics of those who have been hospitalised, and ultimately died, due to COVID-19 compared with the general population prevalence in these determinants, we have developed an objective risk stratification (ORS) tool. Creation of such an objective tool that can be applied equally and without favour to all healthcare practitioners allows biological risk to be evaluated and is used to reduce hazard.

## METHODS

We reviewed the published literature (including multiple search strategies in MEDLINE with PubMed interface) and EMBASE and critically assessed early reports on

medRxiv, a preprint server (<https://www.medrxiv.org/>) (date of last search: 21 April 2020).

## Eligibility criteria

Studies were included according to the following criteria.

## Search terms

COVID-19, Coronavirus, SARS-CoV2, Coronavirus AND mortality, hospitalisation.

## Participants

As it had already been observed that there were differences in the impact of COVID-19 in different geographic locations and different socioeconomic circumstances, we limited the search to reports from the UK.

## Outcomes

Given there are selection biases in testing for coronavirus, COVID-19 care and reporting, we predominantly explored the 'hard outcomes' of admission to the ICU and mortality. Although the occurrence of mild symptoms and asymptomatic disease may have an impact on the ability of health systems to function and on nosocomial spread, it would not cause significant long-term consequences and thus was not considered as an outcome.

## Ethics statement

This project was based on secondary analysis of existing data; therefore, ethics approval was not required.

## Information sources and search strategy

We searched the following electronic databases: MEDLINE, EMBASE and the preprint server medRxiv from inception to 22 April 2021. Only English-language articles were included. The reference lists of included reports were also searched for additional reports. The majority of the existing analyses are based on retrospective and often single-centre series. No published or completed prospective cohort studies or randomised controlled trials were present in this literature search. We reviewed the case reports and cohort studies and, where possible, the local demographics. Because of the urgency to improve risk stratification in the middle of the ongoing pandemic, reports were considered that otherwise would not have met the rigours of a systematic review. All reports were assessed for risk of bias (ROB) using the Cochrane ROB V.2.0 tool<sup>11</sup>; however, this assessment was used to inform the weighting given to the information contained there when being reviewed by the experts to form a consensus risk assessment tool.

The nature of the risk tool was the subject of several focus group meetings. The requirement was for it to be simple to complete, be objective such that it could stratify the vulnerability of exposure and not reveal personal information because it may be misused by 'line managers' after the pandemic. The latter requirement was a particular request from the BAME representatives to the focus groups, who feel that they are particularly vulnerable to workplace bullying.<sup>12</sup> This results in the requirement for a

single-page risk assessment tool that presents cumulative factors that could be completed ahead of a conversation with the designated manager and a clear stratification of vulnerability.

Risk of hospitalisation and mortality was analysed compared with population prevalence. Multivariate Cox regression modelling was used to estimate adjusted HR. Risk was normalised to a female aged 40–49 years, and an integer to approximate the impact of demographics, such as age,<sup>13</sup> ethnicity<sup>14</sup> and important comorbidities,<sup>15</sup> was assigned.

There are two principal sources of data: the Intensive Care National Audit and Research Centre (ICNARC) report that collated data from the national clinical audit covering all NHS adult, general intensive care and combined intensive care/high dependency units in England, Wales and Northern Ireland, plus some additional specialist and non-NHS critical care units, and the OpenSafely report that quantified a range of risk factors for death from COVID-19 based on primary care records.<sup>16</sup> Given these two principal sources of data, we collated and compared the risk of admission to intensive therapy unit (ITU) and mortality from the ICNARC study with the general population data.<sup>17</sup> Predictive risk modelling was used to predict the vulnerability of individuals.

This risk tool was standardised to the risk of mortality of a female under the age of 50 years. A point was then allocated for each approximate doubling in risk. Given the likely colinearity of multiple risk factors where risk was a greater multiple than 2, it was rounded down. As the purpose of this objective risk assessment tool is to supplement rather than supplant existing Public Health England recommendations, characteristics that warranted shielding according to the NHS Digital shielded patient list algorithm were discounted. Risk factors were only included in the derived objective risk assessment tool if they CI of their independent predictive role did not cross the line of unity (ie,  $p < 0.05$ ). Receiver operating characteristic curves were used to identify the scores that would best identify high risk (risk of admission to ITU or death) or moderate risk (risk of hospitalisation but no long-term complications).

Once a simplified risk tool was compiled, it was validated using the composite HRs derived from the OpenSafely platform report.<sup>18</sup> We evaluated the risk in 317 cases within a trust and stratified them into low, middle and high risk. Agreement between the objective risk assessment tool and the calculated HR was evaluated using Cohen's kappa coefficient for inter-rater agreement.

## RESULTS

Multiple global observational studies were identified describing the risk of hospitalisation and mortality due to COVID-19; however, there was significant heterogeneity in these studies, such that the robust nature of the data when applying to a UK population of healthcare providers was questionable (online supplemental table

**Table 1** Clinical demographics

Age group	Mortality
<50 years	1 (reference)
50–69 years	4.02 (95% CI, 2.88 to 5.63)
70–79 years	9.59 (95% CI, 6.89 to 13.3)
≥80 years	13.59 (95% CI, 9.79 to 18.85)
<b>Sex at birth</b>	
Proportion of admissions	
Male	60.2%
Female	39.8%
<b>Mortality once admitted</b>	
Male	1.2 (95% CI, 1.11 to 1.29)
Female	1 (reference)
<b>Composite risk</b>	
Male	1.96
Female	1 (reference)

Mortality by age group and risk of admission and subsequent mortality stratified by sex at birth (features of 16 749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol).<sup>18</sup>  
ISARIC, International Severe Acute Respiratory and Emerging Infection Consortium.

1). One point of agreement, however, was that multiple comorbidities appeared to confer cumulative risk. As a result, the development of a risk calculator was based exclusively on UK data, with multiple comorbidities being given additional weighting.

## Clinician demographics

### Age and sex

In all age groups, mortality was at least twice as high in men compared with women (table 1). Compared with those under the age of 50 years, in men mortality doubled in the age group of 50–59 years, quadrupled in the age group of 60–69 years and was 12 times higher in those aged above 70 years.

### Ethnicity

People of non-white ethnic origin were at a higher risk of hospitalisation and mortality than the general population. Raw data suggested there was a 2-fold to 4-fold increased risk compared with the local population for COVID-19 compared with non-COVID-19 viral pneumonia over the previous 3 years.<sup>19</sup> This was, in part, explained by the premature onset of comorbidities that also conferred risk, such as type 2 diabetes, ischaemic heart disease and stroke.<sup>20–23</sup> After multivariate adjustment, however, some of this risk could not be accounted for with conventional risk factors, and therefore an ethnicity adjustment was included. This is most accentuated in people of black African descent where the risk was 2-fold elevated compared with those of white European descent. People of Indian Asian descent also had an approximately 50%



increased risk of hospitalisation compared with their European counterparts.

### Socioeconomic status

For influenza, 25% of ICU admissions are people from the most deprived quintile compared with just 15% from the least deprived (online supplemental table 2). Once on ITU, however, there were only slight differences in mortality between people in the most deprived and least deprived status.

### Comorbidities

There are multiple comorbid factors that are each incrementally associated with increased mortality. The most common recorded comorbidities are chronic cardiac disease (29%), uncomplicated diabetes (19%), chronic pulmonary disease excluding asthma (19%) and asthma (14%) (online supplemental table 2).<sup>24</sup> These represented 16 749 patients: 7924 (47%) patients had no documented reported comorbidity. Although numerically not a large percentage of patients, those with active malignant neoplasms, chronic kidney disease or liver disease were between 3-fold and 5-fold increased risk of hospitalisation, respectively, compared with the prevalence in the general population. Although data were sparse, there was a suggestion that other conditions requiring long-term immunosuppressant therapy was similarly over-represented by approximately 50% (data not shown). Similarly, dementia was associated with a significantly higher risk of both hospitalisation (~7.7 times increase) and mortality in hospital (39% increase) than the general population. There has been limited relevance for modifying clinical exposure, although it may be pertinent if using this tool to assess risk within the community. Contrary to many popular media reports, the increased risk of hospitalisation and mortality for people living with obesity was, in the first stages, accounted for by comorbidities such as diabetes, ischaemic heart disease and stroke. Beyond a body mass index of 35 kg/m<sup>2</sup> (or 30 kg/m<sup>2</sup> in people of Asian and black African descent), however, there was an independent predictive increased risk.

### Generating an ORS tool

By considering each of the demonstrated associated factors for COVID-19 hospitalisation and subsequent mortality, a risk stratification tool was generated, which may be considered when allocating clinical individuals to standard or higher risk duties (table 2). The risk model attributes a point for every approximate doubling of risk compared with the reference population (HR ≥1.75 and ≤2.25). By adding the risk score from each category, it gives every individual a personal risk score that provides an estimate of their biological hazard. A high risk score was defined

When validating this tool against the 317 predefined cases in a single NHS trust, the outcomes of the ORS tool correlated well with absolute risk scores in the OpenSafely platform (Cohen's kappa, 0.76; SD, 0.071; p<0.0001;

**Table 2** Suggested objective risk stratification tool for individuals not already identified as 'vulnerable' by the NHS Digital shielded patient list

Risk factor	Indicator	Adjustment
Age	>50	1
	>60	2
	>70	4
	>80	6
Sex at birth	Female	0
	Male	1
Ethnicity	White European	0
	Black African descent	2
	Indian Asian descent	1
	Filipino descent	1
	Other (including Mixed race)	1
Diabetes and obesity	(Type 1 or type 2) uncomplicated*	1
	(Type 1 or type 2) complicated*	2
Cardiovascular disease	BMI ≥35 kg/m <sup>2</sup> (>30 kg/m <sup>2</sup> if of BAME descent)	1
	Angina, previous MI, stroke or cardiac intervention	1
	Heart failure	2
Pulmonary disease	Asthma	1
	Non-asthma chronic pulmonary disease	1
	Either of the above requiring oral corticosteroids in the previous year	1
Malignant neoplasm	Active malignancy	3
	Malignancy in remission	1
CKD	CKD 3 or 4	2
	End-stage renal disease/transplant	4
Chronic liver disease	Any active disease	3
Immunosuppressant therapy	Any indication	1
Interpretation	Score	
Low risk	<3	
Medium risk	3–5	
High risk	≥6	

\*Complicated diabetes=presence of microvascular complications or HbA1c ≥64 mmol/mol.

BAME, black, Asian and minority ethnicity; BMI, body mass index; CKD, chronic kidney disease; MI, myocardial infarction; NHS, National Health Service; NHS, National Health Service.

table 3). A final validation was performed against the Public Health England document 'Disparities in the risk and outcomes of COVID-19'.<sup>10</sup> This demonstrated a similarly high level of agreement (Cohen's kappa, 0.81; SD, 0.063; p<0.0001).

### Pregnancy

There are currently insufficient data to make any meaningful assessment about the risk of COVID-19 to either the mother or the unborn child. Early reports from

**Table 3** Validation of the ORS tool compared with the OpenSafely Platform report.

	OpenSafely platform report			Total number of subjects
	≤3-fold increased risk	3-fold to 6-fold increased risk	≥6-fold increased risk	
<b>ORS tool</b>				
Score <3	208	11	0	219
PPV	91.6%			
Score 3–5	19	57	3	79
PPV		77.0%		
Score ≥6	0	6	13	19
PPV			81.3%	
Total	227	74	16	317

Number of healthcare workers scoring low, medium and high risk in a validation exercise of the two tools using data from 317 individuals working in the healthcare system.

Cohen's kappa for agreement is 0.76;  $p < 0.0001$ .

ORS, objective risk stratification; PPV, positive predictive value.

the UK and the USA suggest there is no risk to either; however these are based on small numbers.<sup>25 26</sup> Given the unknown risk to both parties, although pregnancy is not considered as a risk factor in its own right, we would recommend all people who are pregnant be regarded as high risk and offered the option to shield.

## DISCUSSION

There are currently no reliable data for COVID-19-related deaths in healthcare professionals, including doctors, and surprisingly few data on the differences in risk in different healthcare settings. There is an urgent need for high-quality research. We have applied general population risk factors to healthcare workers to generate a simplified biological risk stratification tool and made this freely available on the British Medical Association's website at <https://www.bma.org.uk/media/3820/bma-covid-19-risk-assessment-tool-february-2021.pdf>. This may serve to inform employers when allocating specific duties within the healthcare provision system to fulfil their duty of care to their employees.

There are three types of risk for medical staff. The first relates to their biology, the second to their environment and the third to the exposure. This tool evaluates the former to advise mitigation of the latter by stratifying individuals to lower, medium and higher risk. This biological risk assessment tool does not in any way replace the need for universal precautions with appropriate personal protective equipment (PPE). It should only be used to inform the need for modification of allocated duties to roles with little or no direct contact with patients, such as 'advice and guidance' services or virtual clinic provision. It incorporates and weights recognised risk factors. Many of these factors are predictable, such as age, gender and

pre-existing respiratory disease, all of which have been associated with many previous viral infections such as H1N1 influenza.

The importance of pre-existing cardiovascular disease and cerebrovascular disease is a novel observation for a respiratory disease. This may be due to the method of cellular invasion of SARS-CoV-2 using the ACE2 enzyme, an enzyme which is responsible for physiological vascular health responses to hypertension and obesity. It does not, however, explain the risk associated with diabetes,<sup>27</sup> nor does it account for the increased risk in some ethnic groups.

A recent finding showed that BAME individuals account for 63%, 64% and 95% of deaths in the Nurse, Healthcare Assistant and Doctor staff groups, respectively.<sup>1</sup> These figures are substantially higher than the proportional increase in BAME patients in UK ICUs (mortality of 18% compared with 12% in the general population).<sup>19</sup> Interestingly, our tool distinguished between people of black African descent and people of other non-European backgrounds, awarding a higher risk to those of West African descent. When validating the ORS tool against the OpenSafely report, however, the differential point award demonstrated similar overall predictive role in people of black African descent as other ethnicities. This is likely due to the different confounding disease profile in these populations. People of Indian subcontinent heritage develop additional risk factors such as diabetes and premature cardiovascular disease approximately 10 years earlier than the European counterparts. People of black African descent, however, are more likely to be affected by unmeasured risk factors such as haemoglobinopathies and systemic microvascular dysfunction.<sup>28 29</sup>

## Application of the ORS tool

The primary role of any risk stratification tool is to provide a standardised approach to individual risk management by identifying those with the greatest adverse consequences from hazards.

Once individual risk is stratified, decisions regarding mitigating actions are required. Unfortunately, there remains uncertainty regarding the best action. The impact of recurrent exposure compared with high-risk exposures with high viral load or the environment of the clinical domain is uncertain. Similarly, the relative impact of different environments has not adequately been assessed. Currently, employees in front-line emergency and acute medical settings such as Emergency medicine, anaesthesia, respiratory medicine or gastroenterology may be considered at increased risk, as may be those who may need very close proximity with the patient such as Otorhinolaryngology (Ear Nose and Throat surgery, ENT) and ophthalmology. Some paradoxes have been observed. One recent paper found that the rate of infection with COVID-19 in staff in patient facing occupations was no different from that in clerical/administrative staff without patient contact,<sup>30</sup> suggesting that PPE provides effective protection. Conversely, those later in the disease

process with severe illness (particularly at the time of cytokine storm requiring high dependency care) may have reduced viral load and shedding,<sup>31</sup> therefore paradoxically having a lower potential to transmit infection compared with those at an early stage of the disease with no or relatively mild symptoms.

The ORS tool enables employers to decide when to exclude workers from working in presumed higher risk environments—even if workers do not wish to do so—or modify the nature of their duties to fulfil the employers' legal duty of care obligations to their workforce. It must be acknowledged that this tool is based purely on the biological risk of an individual. The prevalence of the disease in the community is another determinant which should be considered; when prevalence is low, the increased relative risk may not reflect a significant absolute risk, allowing healthcare practitioners to return to their usual role.

### Study limitations

Selection bias in testing, care and reporting can lead to differences in prevalence estimates of pre-existing risk factors and presentation across the reports from various countries. The majority of the existing analyses are based on retrospective and often single-centre series. No published or completed prospective cohort studies or randomised controlled trials were present in this literature search. A limitation is that we only searched PubMed, EMBASE and preprint servers. There is an urgent need for high-quality research using individual-level data for healthcare workers that will allow full mediation analyses to determine whether (for example) it is the age, the diabetes, or the cardiovascular disease that actually carries the greatest prognostic risk, given that these conditions commonly coexist, and explore the disparity in BAME individuals between the deaths in general population and the healthcare workers. There are currently only limited observational data on COVID-19-related deaths in healthcare workers or doctors, again without full access to all potentially pertinent information. Since this tool was developed, there has been significant improvement in the epidemiological recording of the demographics of those who suffer from adverse consequences of COVID-19. The lead author has access to one of the key primary care record databases and uses these data for the regular observation and evaluation of the tool, which is currently on its fifth iteration. Importantly, this tool was, and continues to be, derived from and validated on UK data, and therefore may not be relevant in other countries; however, the methods employed here can be replicated in other healthcare settings.

### Patient and public involvement

The primary target of this research was healthcare professionals, occupational health teams and medical managers. There was significant engagement with members of the British Medical Association—the trade union representing UK doctors—COVID-19 group and the staff members. Several members of this group are

listed as coauthors, including the chair of the representative body. It is important to distinguish that these individuals are reporting personal views based on their branch of practice, and these are not necessarily the views of the Association.

### Concluding remarks and key messages

As part of an employer's legal obligation under the Health and Safety legislation, all individuals are required to have a formal risk assessment. Although many organisations have advocated the need for individualised risk evaluation, there remains no standardised methodology for this assessment. Without a consistent approach to stratification, comparing individuals' personal risk within a department is difficult if not impossible. We have presented a robust scoring tool that allows comparisons and thus decisions to be made regarding the appropriate allocation of duties within a team. This also facilitates open discussion between staff who are being asked to work in patient facing areas and their team leaders so that they also understand their risks. All healthcare workers should wear appropriate PPE for any clinical examination or investigation on the basis that 20%–40% of infected patients, especially if less than 40 years of age, may be asymptomatic.<sup>32</sup> Within a specialty team, the highest risk individuals should be excluded from patient facing clinical areas; those at intermediate risk should have careful consideration to exclude them from front-line areas or given limited duties avoiding close contact such as in ENT, ophthalmology and dentistry. Those at the lowest risk may be assigned duties with more patient contact. Neither the ORS tool nor any other risk score negates the need for good PPE and training.

### Author affiliations

- <sup>1</sup>Diabetes and Vascular Research Centre, University of Exeter Medical School, Exeter, UK
- <sup>2</sup>Academic Department of Healthcare for Older People, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK
- <sup>3</sup>Institute of Clinical Trials, University College London, London, UK
- <sup>4</sup>Medical Microbiology and Infectious Diseases, Swansea University Medical School, Swansea, UK
- <sup>5</sup>Public Health Medicine, London, UK
- <sup>6</sup>Faculty of Public Health, London, UK
- <sup>7</sup>Chair of Representative Body, British Medical Association, London, UK
- <sup>8</sup>Public Health Medicine, North West Commissioning Support Unit, Oldham, UK
- <sup>9</sup>Department of Primary Care and Public Health, Imperial College London, London, UK

**Twitter** W David Strain @DocStrain

**Acknowledgements** We thank the doctors from many branches of practice who gave comments and suggestions. We would also like to thank Professor Dame Parveen Kumar of Queen Mary University of London for helpful comments. WDS is supported by the NIHR Exeter Clinical Research Facility and the NIHR Collaboration for Leadership in Applied Health Research and Care (CLAHRC) for the South West Peninsula. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR Exeter Clinical Research Facility, the NHS, the British Medical Association, the NIHR or the Department of Health and Social Care in England.

**Contributors** JJ and WDS came up with the design and authored the first draft. WDS, JJ, APD, PE, EF HM SS and MR have all contributed to the format of the analyses and contributed to the iterations of this manuscript. WDS is responsible for the integrity of the analysis.



**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** All data relevant to the study are included in the article or uploaded as supplementary information. This manuscript is based on a secondary analysis of published data. The analysis plan and Stata output are available on contact with WDS.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

## ORCID iD

W David Strain <http://orcid.org/0000-0002-6826-418X>

## REFERENCES

- Cook T, Kursumovic E, Lennane S. Exclusive: deaths of NHS staff from covid-19 analysed. *Health Service J* 2020.
- Office for National Statistics O. Deaths involving COVID-19, England and Wales: deaths occurring in April 2020, 2020. Available: <https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsinvolvedcovid19englandandwales/deathsoccurringinapril2020> [Accessed 28 May 2020].
- Givi B, Schiff BA, Chinn SB, et al. Safety recommendations for evaluation and surgery of the head and neck during the COVID-19 pandemic. *JAMA Otolaryngol Head Neck Surg* 2020;146:579.
- Greenland JR, Michelow MD, Wang L, et al. COVID-19 infection: implications for perioperative and critical care physicians. *Anesthesiology* 2020;132:1346–61.
- Lai J, Ma S, Wang Y, et al. Factors associated with mental health outcomes among health care workers exposed to coronavirus disease 2019. *JAMA Netw Open* 2020;3:e203976.
- Lai THT, Tang EWH, Chau SKY, et al. Stepping up infection control measures in ophthalmology during the novel coronavirus outbreak: an experience from Hong Kong. *Graefes Arch Clin Exp Ophthalmol* 2020;258:1049–55.
- NHS England.. Patient deaths report 2020. Available: <https://www.england.nhs.uk/statistics/statistical-work-areas/covid-19-daily-deaths/> [Accessed 1 May 2020].
- NHS Employers. Risk assessments for staff 2020. Available: <https://www.nhsemployers.org/covid19/health-safety-and-wellbeing/risk-assessments-for-staff>
- Khunti K, Singh AK, Pareek M, et al. Is ethnicity linked to incidence or outcomes of covid-19? *BMJ* 2020;369:m1548.
- Public Health England. Disparities in the risk and outcomes of COVID-19 2020. Available: [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/889195/disparities\\_review.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/889195/disparities_review.pdf) [Accessed 2 Jun 2020].
- Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011;343:d5928.
- Carter M, Thompson N, Crampton P, et al. Workplace bullying in the UK NHS: a questionnaire and interview study on prevalence, impact and barriers to reporting. *BMJ Open* 2013;3:e002628.
- Verity R, Okell LC, Dorigatti I. Estimates of the severity of coronavirus disease 2019: a model-based analysis. *Lancet Infect Dis* 2020.
- Office of National Statistics. UK population by ethnicity 2020. Available: <https://www.ethnicity-facts-figures.service.gov.uk/uk-population-by-ethnicity> [Accessed 1 May 2020].
- Wang B, Li R, Lu Z, et al. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. *Aging* 2020;12:6049–57.
- Williamson E, Walker AJ, Bhaskaran KJ. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. *medRxiv* 2020.
- Doidge JC, Gould DW, Ferrando-Vivas P, et al. Trends in intensive care for patients with COVID-19 in England, Wales, and Northern Ireland. *Am J Respir Crit Care Med* 2021;203:565–74.
- Coggon D, Croft P, Cullinan P. Assessment of workers' personal vulnerability to COVID-19 using 'COVID-AGE'. *medRxiv* 2020.
- Docherty AB, Harrison EM, Green CA. Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC who clinical characterisation protocol. *medRxiv* 2020.
- Hills AP, Arena R, Khunti K, et al. Epidemiology and determinants of type 2 diabetes in South Asia. *Lancet Diabetes Endocrinol* 2018;6:966–78.
- Bello O, Mohandas C, Shojee-Moradie F, et al. Black African men with early type 2 diabetes have similar muscle, liver and adipose tissue insulin sensitivity to white European men despite lower visceral fat. *Diabetologia* 2019;62:835–44.
- Smeeton NC, Heuschmann PU, Rudd AG, et al. Incidence of hemorrhagic stroke in black Caribbean, black African, and white populations: the South London stroke register, 1995–2004. *Stroke* 2007;38:3133–8.
- Wolfe CDA, Rudd AG, Howard R, et al. Incidence and case fatality rates of stroke subtypes in a multiethnic population: the South London stroke register. *J Neurol Neurosurg Psychiatry* 2002;72:211–6.
- Wynants L, Van Calster B, Collins GS, et al. Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal. *BMJ* 2020;369:m1328.
- Knight M, Bunch K, Vousden N, et al. Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study. *BMJ* 2020;369:m2107.
- Adhikari EH, Moreno W, Zofkie AC, et al. Pregnancy outcomes among women with and without severe acute respiratory syndrome coronavirus 2 infection. *JAMA Netw Open* 2020;3:e2029256.
- Tikellis C, Johnston CI, Forbes JM, et al. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. *Hypertension* 2003;41:392–7.
- Strain WD, Chaturvedi N, Leggetter S, et al. Ethnic differences in skin microvascular function and their relation to cardiac target-organ damage. *J Hypertens* 2005;23:133–40.
- Strain WD, Chaturvedi N, Nihoyannopoulos P, et al. Differences in the association between type 2 diabetes and impaired microvascular function among Europeans and African Caribbeans. *Diabetologia* 2005;48:2269–77.
- Hunter E, Price DA, Murphy E, et al. First experience of COVID-19 screening of health-care workers in England. *Lancet* 2020;395:e77–8.
- Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. *Nature* 2020;581:465–9.
- Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 2020;579:270–3.

Supplementary Table 1.  
Co-morbidities associated with higher mortality in international studies

Author N in study	Guan 1590	Yang 46428	Zhou 191	Huang 41	Chen 99	Yang 52	Zhang 140	CDC 7162 USA	Onder 355 Italy	CSG 481 Italy
>1 comorbidity	25%		48%	32%	51%	40%		38%		
0 comorbidity										1.2%
1 comorbidity										23.5%
2 co-morbidity										26.6%
3+ comorbidities										48.6%
Hypertension	17%	17%	30%	15%			30%			74%
IHD	54%	5%	8%	15%	40%	10%		9%	30%	30%
Diabetes	8%	5%	19%	20%		9%	12%	11%	36%	34%
Cancer	1.1%				1%	4%			25%	19.5%
Cerebrovascular disease	2%					13%				11.2%
Respiratory disease		2.4%			1%		0%	9%		
COPD	1.5%					8%	1.4%			14%
Kidney disease	1.3%							3%		20%
Immunodeficiency	0.2%							4%		
Obesity								0.2%		



**Supplementary Table 2 - Composite risk of contracting COVID-19 and mortality by pre-existing co-morbidity**

	Prevalence in COVID-19 <sup>1</sup>	Prevalence in population	Relative risk of contracting disease	Additional Risk of mortality (18)	Composite increased risk
Chronic Cardiac Disease	29%	14% <sup>2</sup>	2.07	1.31	2.71
Uncomplicated diabetes	19%	4.8% <sup>3</sup>	3.95	N/A	3.95
Chronic pulmonary disease excluding asthma	16%	4.5% <sup>4</sup>	3.56	1.19	4.2
Asthma	14%	8.3% <sup>5</sup>	2.15	1.19	2.55
Dementia	10%	1.3% <sup>6</sup>	7.69	1.39	6
Malignant neoplasm	9%	1.5% <sup>7</sup>	6.00	1.19	8.45
On Immunosuppressant therapy	9%	0.8% <sup>8</sup>	11.25	N/A	11.25
Obesity (BMI>35kg/m <sup>2</sup> )	38.5%	27.8% <sup>3</sup>	1.38	1.37	1.90
Diabetes (with complications)	6%	1.2% <sup>3</sup>	5.00	N/A	5

## Objective Risk Stratification tool for staff working with COVID-19

2

## References

1. Docherty AB, Harrison EM, Green CA, et al. Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. *medRxiv* 2020: 2020.04.23.20076042.
2. NHS Digital. Health Survey for England 2017. 2018. Health Survey for England 2017 [NS] - NHS Digital (accessed 1st May 2020).
3. Diabetes UK. Facts and figures 2019. <https://www.diabetes.org.uk/professionals/position-statements-reports/statistics> (accessed 28th April 2020).
4. British Lung Foundation. The UK big picture 2019. <https://statistics.blf.org.uk/lung-disease-uk-big-picture> (accessed 28th April 2020).
5. Asthma UK. Facts and Figures. 2019. <https://www.asthma.org.uk/about/media/facts-and-statistics/> (accessed 28th April 2020).
6. Alzheimers UK. Dementia Statistics Hub 2018. <https://www.dementiastatistics.org/statistics-about-dementia/prevalence/> (accessed 28th April 2020).
7. Cancer Research UK. Cancer Statistics for the UK 2019. <https://www.cancerresearchuk.org/health-professional/cancer-statistics-for-the-uk> (accessed 28th April 2020).
8. Arthritis UK. The state of musculoskeletal health 2019. 2019. <https://www.versusarthritis.org/media/14594/state-of-musculoskeletal-health-2019.pdf> (accessed 28th April 2020).